抗原
佐剂
免疫原性
病毒学
白喉
重组DNA
医学
免疫学
接种疫苗
生物
生物化学
基因
作者
Prashant Kumar,David A. Holland,Kathryn Secrist,Poorva Taskar,Brandy Dotson,Soraia Saleh-Birdjandi,Yetunde Adewunmi,Jennifer Doering,Nicholas J. Mantis,David B. Volkin,Sangeeta B. Joshi
出处
期刊:Vaccines
[MDPI AG]
日期:2024-06-03
卷期号:12 (6): 609-609
标识
DOI:10.3390/vaccines12060609
摘要
Introducing new recombinant protein antigens to existing pediatric combination vaccines is important in improving coverage and affordability, especially in low- and middle-income countries (LMICs). This case-study highlights the analytical and formulation challenges encountered with three recombinant non-replicating rotavirus vaccine (NRRV) antigens (t-NRRV formulated with Alhydrogel® adjuvant, AH) combined with a mock multidose formulation of a pediatric pentavalent vaccine used in LMICs. This complex formulation contained (1) vaccine antigens (i.e., whole-cell pertussis (wP), diphtheria (D), tetanus (T), Haemophilus influenza (Hib), and hepatitis B (HepB), (2) a mixture of aluminum-salt adjuvants (AH and Adju-Phos®, AP), and (3) a preservative (thimerosal, TH). Selective, stability-indicating competitive immunoassays were developed to monitor binding of specific mAbs to each antigen, except wP which required the setup of a mouse immunogenicity assay. Simple mixing led to the desorption of t-NRRV antigens from AH and increased degradation during storage. These deleterious effects were caused by specific antigens, AP, and TH. An AH-only pentavalent formulation mitigated t-NRRV antigen desorption; however, the Hib antigen displayed previously reported AH-induced instability. The same rank-ordering of t-NRRV antigen stability (P[8] > P[4] > P[6]) was observed in mock pentavalent formulations and with various preservatives. The lessons learned are discussed to enable future multidose, combination vaccine formulation development with new vaccine candidates.
科研通智能强力驱动
Strongly Powered by AbleSci AI